NovoSeven RT® (coagulation factor VIIa [recombinant])

NovoSeven RT is covered for intravenous use for FDA‑approved indications (treatment and perioperative management of bleeding in hemophilia A/B with inhibitors, congenital FVII deficiency, Glanzmann’s thrombasthenia refractory to platelet transfusion, and acquired hemophilia in adults) and for compendial off‑label prevention of bleeding in those same disorders (non‑IV use is excluded). Coverage requires documentation of the specific diagnosis and meeting the policy's coverage and safety criteria, adherence to the policy’s indication‑specific weight‑based dosing, with initial approval up to 3 months and renewals up to 12 months.

"Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors"

Sign up to see full coverage criteria, indications, and limitations.